Abstract
Heart failure (HF) represents a complex multifactorial syndrome, characterized by crucial structural and functional abnormalities of the myocardium. Matrix metalloproteinases are associated with left ventricular dysfunction, adverse left ventricular remodelling and prognosis after acute myocardial infarction. There is a strong association between oxidative stress and MMPs in the pathophysiology of HF. As MMPs are strongly associated to the pathogenesis and pathophysiology of HF, several agents have been proposed as potential modulators of these molecules. Classical agents such as statins, angiotensin converting enzyme inhibitors (ACEIS) and beta-blockers and a variety of novel agents have been implicated in the pathogenesis and progression of heart failure via the matrix metalloproteinases pathway and consist of possible future therapeutic targets.
Keywords: Clinical implications, dysfunction, heart failure, left ventricle remodeling, matrix metalloproteinases, multifactorial syndrome, oxidative stress, crucial structural, myocardium, ventricular dysfunction, pathophysiology, ventricular remodelling, therapeutic targets, enzyme inhibitors
Current Topics in Medicinal Chemistry
Title:Matrix Metallopropteinases in Heart Failure
Volume: 12 Issue: 10
Author(s): Dimitris Tousoulis, Anna-Maria Kampoli, Nikolaos Papageorgiou, Charalambos Antoniades, Gerasimos Siasos, George Latsios, Eleftherios Tsiamis and Christodoulos Stefanadis
Affiliation:
Keywords: Clinical implications, dysfunction, heart failure, left ventricle remodeling, matrix metalloproteinases, multifactorial syndrome, oxidative stress, crucial structural, myocardium, ventricular dysfunction, pathophysiology, ventricular remodelling, therapeutic targets, enzyme inhibitors
Abstract: Heart failure (HF) represents a complex multifactorial syndrome, characterized by crucial structural and functional abnormalities of the myocardium. Matrix metalloproteinases are associated with left ventricular dysfunction, adverse left ventricular remodelling and prognosis after acute myocardial infarction. There is a strong association between oxidative stress and MMPs in the pathophysiology of HF. As MMPs are strongly associated to the pathogenesis and pathophysiology of HF, several agents have been proposed as potential modulators of these molecules. Classical agents such as statins, angiotensin converting enzyme inhibitors (ACEIS) and beta-blockers and a variety of novel agents have been implicated in the pathogenesis and progression of heart failure via the matrix metalloproteinases pathway and consist of possible future therapeutic targets.
Export Options
About this article
Cite this article as:
Tousoulis Dimitris, Kampoli Anna-Maria, Papageorgiou Nikolaos, Antoniades Charalambos, Siasos Gerasimos, Latsios George, Tsiamis Eleftherios and Stefanadis Christodoulos, Matrix Metallopropteinases in Heart Failure, Current Topics in Medicinal Chemistry 2012; 12 (10) . https://dx.doi.org/10.2174/1568026611208011181
DOI https://dx.doi.org/10.2174/1568026611208011181 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Challenges, Consequences and Possible Treatments of Anticancer Drug Discovery ll
The use of several compounds has been the subject of increasing interest in phytochemistry, biochemistry, and other fields of research at the chemistry-biology-ecosystems interface. In spite of the continued search for new anticancer drugs, cancer remains a leading cause of death. Cancer mortalities are expected to increase to 12.9 million, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aging process, cognitive decline and Alzheimer`s disease: can strength training modulate these responses?
CNS & Neurological Disorders - Drug Targets Aldosterone, Mineralocorticoid Receptor and the Metabolic Syndrome:Role of the Mineralocorticoid Receptor Antagonists
Current Vascular Pharmacology Algorithms and Criteria for Transcatheter Aortic Valve Replacement Patient Selection: Current Status and Future Trends
Current Pharmaceutical Design Peroxisome Proliferator-Activated Receptor-γ in Vascular Biology
Cardiovascular & Hematological Disorders-Drug Targets Automated Electrophysiology in Drug Discovery
Current Pharmaceutical Design Early Development of Symptomatic Drugs in AD: A Systematic Review of the Use of Biomarkers
CNS & Neurological Disorders - Drug Targets ENaC Modulators and Renal Disease
Current Molecular Pharmacology The FDG-PET Revolution of Medical Imaging – Four Decades and Beyond
Current Molecular Imaging (Discontinued) Targeting Heme Oxygenase-1 in Vascular Disease
Current Drug Targets Oxidative Stress Induced Mitochondrial DNA Deletion as a Hallmark forthe Drug Development in the Context of the Cerebrovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Admission, 24 Hours and Discharge Troponin T Among Acute Myocardial Infarction Patients: Differing by Prognostic Contribution
Recent Patents on Biomarkers Update on the Role of Neutrophils in Atherosclerotic Plaque Vulnerability
Current Drug Targets Therapeutic Angiogenesis using Hepatocyte Growth Factor (HGF)
Current Gene Therapy Mevalonate Cascade and Neurodevelopmental and Neurodegenerative Diseases: Future Targets for Therapeutic Application
Current Molecular Pharmacology Hypertension in Diabetes: Optimal Pharmacotherapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Vasopressin in Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Diagnostic Strategy for Suspected Unilateral Absence of the Pulmonary Artery
Current Medical Imaging Atypical Chest Pain in ACS: A Trap Especially for Women
Current Pharmaceutical Design The Roles of Cytochrome P450 in Ischemic Heart Disease
Current Drug Metabolism Anti-Vascular Endothelial Growth Factor (VEGF) Therapy: A New Cause of Hypertension
Current Hypertension Reviews